Stock listing

NASDAQ:OKUR OnKure Therapeutics, Inc. Stock

Home listing (NASDAQ) of OnKure Therapeutics, Inc.

Follow OnKure Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:OKUR

$2.70 USD -0.12 (-4.3%)

Close on Nov 20, 2026

Past year +3.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.68 – $2.81 USDNov 20, 2026
Volume
195,211 sharesNov 20, 2026
Market cap
$109.4M USDAt the close on Nov 20, 2026 · price × 40.50M shares outstanding
52-week range
$2.01 – $5.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$911,397 USDMedian day 240,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
OnKure Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:OKUR · Home$2.70 USD-0.12 (-4.3%)195,211$2.75$2.81$2.682$2.82Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OKUR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.70-0.12-4.3%$2.75$2.81$2.682195,211
$2.82+0.24+9.3%$2.59$2.84$2.575172,685
$2.58-0.17-6.2%$2.60$2.81$2.50228,165
$2.75+0.12+4.6%$2.55$2.805$2.50682,256
$2.63-0.38-12.6%$3.03$3.08$2.60891,350
$3.01-0.35-10.4%$3.33$3.33$2.935286,825
$3.36-0.025-0.7%$3.40$3.59$3.345205,829
$3.385+0.195+6.1%$3.15$3.42$2.99281,838
$3.19+0.325+11.3%$2.88$3.21$2.76814,191
$2.865+0.34+13.5%$2.47$2.88$2.31555,817
$2.525-0.065-2.5%$2.54$2.57$2.315325,164
$2.59+0.09+3.6%$2.53$2.63$2.51876,952
$2.50-0.09-3.5%$2.60$2.60$2.44219,375
$2.59-0.03-1.1%$2.64$2.72$2.48500,840
$2.620.000.0%$2.61$2.67$2.53306,762
$2.62-0.01-0.4%$2.63$2.665$2.44427,588
$2.63+0.035+1.3%$2.56$2.661$2.46282,588
$2.595+0.12+4.8%$2.49$2.72$2.475320,237
$2.475-0.045-1.8%$2.53$2.625$2.38258,090
$2.52-0.06-2.3%$2.62$2.62$2.48240,900
$2.58+0.28+12.2%$2.30$2.59$2.28243,800
$2.30-0.06-2.5%$2.37$2.40$2.25232,800
$2.36+0.11+4.9%$2.25$2.475$2.25235,100
$2.25+0.15+7.1%$2.10$2.26$2.02501,500
$2.10-0.03-1.4%$2.14$2.14$2.01386,000
$2.13-0.12-5.3%$2.26$2.28$2.09349,900
$2.25-0.095-4.1%$2.29$2.38$2.21381,200
$2.345-0.075-3.1%$2.40$2.40$2.31232,600
$2.42+0.01+0.4%$2.41$2.47$2.40146,400
$2.41+0.11+4.8%$2.29$2.42$2.23609,200
$2.30-0.05-2.1%$2.34$2.456$2.13519,600
$2.35-0.11-4.5%$2.41$2.46$2.30260,700
$2.46-0.17-6.5%$2.65$2.65$2.41327,500
$2.63+0.07+2.7%$2.56$2.67$2.42626,200
$2.56+0.02+0.8%$2.57$2.61$2.46526,900
$2.54-0.185-6.8%$2.72$2.825$2.502,082,200
$2.725+0.125+4.8%$2.63$2.79$2.50831,400
$2.60-0.16-5.8%$2.78$2.80$2.47339,800
$2.76-0.14-4.8%$2.87$2.879$2.60442,200
$2.90-0.03-1.0%$2.93$3.00$2.8691,400
$2.93-0.01-0.3%$2.96$3.05$2.88149,700
$2.94-0.16-5.2%$3.09$3.24$2.90149,700
$3.10+0.04+1.3%$3.06$3.11$2.91200,800
$3.06+0.11+3.7%$2.95$3.10$2.92166,700
$2.95-0.01-0.3%$2.96$3.08$2.91223,100
$2.96+0.08+2.8%$2.94$3.02$2.82181,000
$2.88-0.05-1.7%$2.93$3.005$2.8483,900
$2.93-0.07-2.3%$2.98$2.98$2.815171,100
$3.00-0.10-3.2%$3.11$3.14$2.978105,200
$3.10-0.17-5.2%$3.31$3.33$2.98253,600
$3.27-0.11-3.3%$3.36$3.42$3.24168,500
$3.38-0.02-0.6%$3.38$3.49$3.31980,100
$3.40-0.18-5.0%$3.55$3.90$3.34115,000
$3.58+0.02+0.6%$3.53$3.62$3.508165,500
$3.56+0.02+0.6%$3.56$3.62$3.52132,200
$3.54-0.02-0.6%$3.54$3.665$3.41127,400
$3.56-0.07-1.9%$3.62$3.70$3.494193,300
$3.63-0.16-4.2%$3.80$3.90$3.54100,500
$3.79-0.04-1.0%$3.83$4.02$3.67432,500
$3.83+0.03+0.8%$3.77$3.86$3.7797,700
$3.80-0.05-1.3%$3.86$4.013$3.7080,000
$3.85-0.04-1.0%$3.91$4.043$3.79116,228
$3.89-0.05-1.3%$3.95$4.39$3.70421,074
$3.94+0.01+0.3%$3.95$4.073$3.9059,900
$3.93-0.15-3.7%$4.04$4.043$3.78103,500

Splits

1 split · NASDAQ:OKUR · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:OKUR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All OnKure Therapeutics, Inc. news

OnKure Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in the last 12 months · 30 in all · newest Nov 4, 2026 · oldest 2021
Decks
6 decks · latest August 2026

Where OnKure Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:OKUR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:OKURBOATSUnited StatesUSD

Valuation

Price/book 0.7× against a median of 2.1×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$53.16M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.17

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
OnKure Therapeutics, Inc. · NASDAQ:OKURUS$109.4M−US$53.16Mn/an/an/a0.7×n/a0.0×1.17
Sinew Pharma, Inc. · TPEX:6634US$114.4MUS$84.23Mn/a59,064×n/a3.6×n/a0.0×n/a
Armata Pharmaceuticals, Inc. · AMEX:ARMPUS$112.7MUS$346.0Mn/a45.8×n/an/an/an/a0.97
Medigen Biotechnology Corporation · TPEX:3176US$111.8MUS$61.95Mn/a1.6×n/a2.5×−19.9%0.8×n/a
Fate Therapeutics, Inc. · NASDAQ:FATEUS$111.7MUS$47.08Mn/a9.9×n/a0.8×n/a0.6×2.25
Spruce Biosciences, Inc. · NASDAQ:SPRBUS$109.2MUS$41.00Mn/an/an/a1.6×n/a0.3×1.73
NIBEC Co., Ltd. · KRX:138610US$108.7MUS$92.50Mn/a5.5×118×3.0×−0.1%0.0×n/a
Jyong Biotech Ltd. · NASDAQ:MENSUS$107.6MUS$125.0Mn/an/an/an/an/an/a1.74
Nykode Therapeutics ASA · OSL:NYKDUS$107.0MUS$62.24Mn/an/an/a1.3×n/a0.0×n/a
JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126US$105.3MUS$84.72Mn/a2.0×n/a1.6×−195.8%0.6×n/a
Genelux Corporation · NASDAQ:GNLXUS$104.3MUS$93.85Mn/a11,732×n/a11.4×n/a0.0×1.52
Median of the othersUS$108.9MUS$84.47M9.9×118×2.1×−19.9%0.2×1.73

Forecasts

5 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
15.25 USD · Analysts' mean
EPS, year to Dec 2026
-1.61 · 2 analysts
Revenue, year to Dec 2026
125K · 4 analysts

Team and board

Officers

OfficerRole
Nicholas A. SaccomanoPresident & Chief Executive Officer
Jason LeveroneChief Financial Officer
Rogan NunnGeneral Counsel and Secretary
Aaron GoodwinVice President of Pharmaceutical Sciences and Supply Chain
David MareskaVice President, Discovery Chemistry
James BlakeSenior Vice President of Computational Drug Discovery
Jim WongVice President, Biological Sciences
Kevin S. LitwilerSenior Vice President of DMPK and Clinical Pharmacology
Mark L. BoysSenior Vice President of Discovery Chemistry
Qian ZhaoVice President and Distinguished Fellow
Robbie AltonSenior Vice President of Clinical Operations
Dylan HartleyChief Scientific Officer
Samuel AgrestaChief Medical Officer

Board

DirectorRole
Michael GreyChairman
Andrew Phillips
Dylan HartleyChief Scientific Officer
Edward Mathers
Isaac Manke
Jason LeveroneChief Financial Officer
Liam Ratcliffe
Nicholas A. SaccomanoPresident & Chief Executive Officer
R. Michael Carruthers
Rogan NunnGeneral Counsel and Secretary
Samuel AgrestaChief Medical Officer
Valerie Jansen

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−2.5%
Q2 2026Aug 4, 2026 · After close+1.5%
Q1 2026May 5, 2026 · After close−10.0%
Q4 2025Mar 13, 2026+10.8%
Q3 2025Nov 6, 2025 · After close−7.0%
Q2 2025Aug 12, 2025 · After close+20.0%
Q1 2025May 5, 2025 · Before open+0.4%
Q4 2024Mar 10, 2025 · After close−0.2%
Q3 2024Nov 7, 2024 · After close+2.3%
Q2 2024Aug 13, 2024+9.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024+5.8%
Q4 2023Mar 28, 2024+3.0%
Q3 2023Nov 13, 2023−0.9%
Q2 2023Aug 10, 2023−6.3%
Q1 2023May 11, 2023+1.8%
Q4 2022Mar 27, 2023−10.3%
Q3 2022Nov 8, 2022−3.0%
Q2 2022Aug 9, 2022−3.0%
Q1 2022May 11, 2022−11.7%
Q4 2021Mar 24, 2022−4.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck18 slidesAugust 2026
Technical Presentation (July 2026)Technical27 slidesJul 15, 2026
Investor Presentation (June 2025)Investor deck21 slidesJun 26, 2025
San Antonio Breast Cancer Symposium 2024Conference14 slidesDec 10, 2024
Investor Presentation (December 2024)Investor deck21 slidesDec 10, 2024
Reneo Pharmaceuticals — Merger or Acquisition (May 2024)Merger or acquisition25 slidesMay 13, 2024

Open Decks

IPO

Went public as Reneo Pharmaceuticals, Inc. Priced at US$15.00 a share on Apr 8, 2021.

Price
US$15.00 a share
Shares offered
6,250,000 shares of common stock
Offering size
US$93.8 million
Underwriters' option
Up to 937,500 more shares
Underwriters
Jefferies, SVB Leerink, Piper Sandler · In the order on the cover
Shares delivered
On or about Apr 13, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 12, 2021
Filed publiclyMar 19, 2021
Amended onceApr 5, 2021
Shares registered with an exchangeApr 6, 2021
Declared effective by the SECApr 8, 2021
Final prospectus, with the priceApr 9, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Apr 9, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue0000
Cost of revenue830.0K662.0K560.0K529.0K50.0K37.0K
Gross profit-830.0K-662.0K-560.0K-529.0K-50.0K-37.0K
Research and development48.3M43.8M32.1M37.7M28.2M15.9M
Selling, general and administrative14.7M10.6M4.82M3.90M
Operating income-63.0M-54.4M-36.9M-53.8M-39.8M-19.6M
Depreciation and amortization447.0K459.0K417.0K88.0K50.0K37.0K
EBITDA-62.5M-53.9M-36.5M-53.8M-39.8M-19.5M
Interest expense8.00K300.0K0
Income before tax-59.5M-52.7M-77.4M-52.0M-39.8M-19.5M
Income tax000000
Net income-59.5M-52.7M-35.3M-52.0M-39.8M-19.5M
Earnings per share, basic-4.40-15.28-124.41-2.12-2.19-9.60
Earnings per share, diluted-4.40-15.28-124.41-2.12-2.19-9.60

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents59.0M110.8M29.9M19.9M124.7M53.6M
Short-term investments075.3M81.2M23.0M
Current assets60.8M113.0M33.8M106.4M153.7M55.0M
Property, plant and equipment618.0K1.02M1.43M453.0K212.0K69.0K
Total assets62.1M114.9M35.7M108.2M154.0M55.2M
Accounts payable1.43M2.97M3.42M1.89M2.02M908.0K
Current liabilities5.92M10.5M7.29M7.12M6.20M4.58M
Total debt549.0K1.08M674.0K637.0K92.7M
Total liabilities5.93M11.1M7.75M8.21M6.81M4.62M
Shareholders' equity56.2M103.8M-101.8M-54.4M147.2M-42.1M
Shares outstanding40.5M40.5M3.34M24.7M24.5M2.05M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-51.8M-51.1M-34.5M-47.4M-38.0M-18.5M
Capital spending-46.0K-52.0K-246.0K-346.0K-198.0K-24.0K
Free cash flow-51.9M-51.2M-34.8M-47.7M-38.2M-18.6M
Cash from investing-46.0K15.9M-246.0K-57.8M-23.4M7.38M
Cash from financing163.0K116.1M53.1M471.0K132.4M47.3M
Share buybacks-4.40M
Change in cash-51.7M80.9M18.3M-104.7M71.0M36.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 20, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 4, 2026ResultsSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeOct 7, 2026Big-stake noticeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
4/A · Change in ownership, amendedAug 13, 2026Insider tradeSEC
8-K · Current reportAug 12, 2026Management or board changeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 10, 2026Big-stake noticeSEC
424B5 · ProspectusAug 4, 2026Offer documentSEC
8-K · Current reportAug 4, 2026ResultsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 5, 2026Offer documentSEC
8-K · Current reportJun 4, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMay 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 5, 2026ResultsSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 5, 2026Other filingsSEC
CORRESP · Letter to the SECApr 30, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 30, 2026Other filingsSEC
S-3 · Registration statementApr 24, 2026Offer documentSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
3 · Initial statement of ownershipApr 7, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeApr 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 1, 2026Big-stake noticeSEC
8-K · Current reportMar 30, 2026Material contractSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 28, 2025Big-stake noticeSEC
424B3 · ProspectusNov 21, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 19, 2025Other filingsSEC
POS AM · Amendment to an effective registrationNov 6, 2025Offer documentSEC
S-3 · Registration statementNov 6, 2025Offer documentSEC
424B3 · ProspectusNov 6, 2025Offer documentSEC
8-K · Current reportNov 6, 2025Material contractSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Current reportSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 29, 2025Big-stake noticeSEC
424B3 · ProspectusMay 28, 2025Offer documentSEC
8-K · Current reportMay 28, 2025Meeting outcomeSEC
3 · Initial statement of ownershipMay 27, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeMay 22, 2025Big-stake noticeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 19, 2025Big-stake noticeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
424B3 · ProspectusMay 6, 2025Offer documentSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 16, 2025Annual reportSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
424B3 · ProspectusMar 24, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 24, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 20, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 10, 2025Offer documentSEC
424B3 · ProspectusMar 10, 2025Offer documentSEC
8-K · Current reportMar 10, 2025ResultsSEC
10-K · Annual reportMar 10, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 31, 2025Big-stake noticeSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 21, 2025Big-stake noticeSEC
424B3 · ProspectusDec 10, 2024Offer documentSEC
8-K · Current reportDec 10, 2024Current reportSEC
S-8 · Registration statement for employee plansDec 9, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
424B3 · ProspectusNov 7, 2024Offer documentSEC
8-K · Current reportNov 7, 2024Current reportSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
424B3 · ProspectusOct 31, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 31, 2024Other filingsSEC
CORRESP · Letter to the SECOct 28, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedOct 28, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECOct 25, 2024Other filingsSEC
S-1 · Registration statementOct 23, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedOct 23, 2024Big-stake noticeSEC
DOct 21, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedOct 16, 2024Big-stake noticeSEC
3 · Initial statement of ownershipOct 15, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 10, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 10, 2024Big-stake noticeSEC
3 · Initial statement of ownershipOct 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 9, 2024Big-stake noticeSEC
4 · Change in ownershipOct 9, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 8, 2024Big-stake noticeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2024Insider tradeSEC
8-K · Current reportOct 8, 2024Acquisition or disposalSEC
425Oct 2, 2024Other filingsSEC
8-K · Current reportOct 2, 2024Meeting outcomeSEC
SC 13G · Big-stake noticeSep 26, 2024Big-stake noticeSEC
4 · Change in ownershipSep 26, 2024Insider tradeSEC
425Sep 20, 2024Other filingsSEC
8-K · Current reportSep 20, 2024Current reportSEC
4 · Change in ownershipSep 19, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
8-K · Current reportSep 13, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveAug 27, 2024Other filingsSEC
424B3 · ProspectusAug 26, 2024Offer documentSEC

This page holds 200 of 406 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from OnKure Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
40,503,094
Fully diluted
40,503,094

Fully diluted

LineSharesAs of
Common shares40,503,094Nov 2, 2026

Share count over time

CountShares
Nov 2, 202640,503,094

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Bvf Inc4.05M10.0%US$11MSep 30, 2026
Ra Capital Management, L.P.4M9.9%US$10.9MSep 30, 2026
Acorn Capital Advisors, LLC2.84M7.0%US$7.75MSep 30, 2026
StepStone Group LP2.66M6.6%US$7.24MSep 30, 2026
ADAR1 Capital Management, LLC2.24M5.5%US$6.1MSep 30, 2026
Vivo Capital, LLC1.93M4.8%US$5.25MSep 30, 2026
Vanguard1.88M4.6%US$5.12MSep 30, 2026
BlackRock1.68M4.1%US$4.57MSep 30, 2026
Prosight Management, LP1.33M3.3%US$3.61MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.2M3.0%US$3.28MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vestal Point Capital, LP1.09M2.7%US$2.96MSep 30, 2026
Sio Capital Management, LLC1.08M2.7%US$2.95MSep 30, 2026
Bank of America1M2.5%US$2.73MSep 30, 2026
Logos Global Management LP964K2.4%US$2.63MSep 30, 2026
Geode Capital720K1.8%US$1.96MSep 30, 2026
Trails Edge Capital Partners, LP620K1.5%US$1.69MSep 30, 2026
Citadel556K1.4%US$1.52MSep 30, 2026
NEA Management Company, LLC479K1.2%US$1.3MSep 30, 2026
State Street473K1.2%US$1.29MSep 30, 2026
Ensign Peak Advisors, Inc361K0.89%US$983KSep 30, 2026
Marshall Wace, LLP355K0.88%US$970KSep 30, 2026
Renaissance Technologies353K0.87%US$962KSep 30, 2026
Sofinnova Investments, Inc.313K0.77%US$852KSep 30, 2026
Carlyle Group Inc.270K0.67%US$735KSep 30, 2026
Seven Fleet Capital Management LP241K0.59%US$657KSep 30, 2026
Dv Equities, LLC241K0.59%US$657KSep 30, 2026
Northern Trust201K0.50%US$547KSep 30, 2026
Stonepine Capital Management, LLC163K0.40%US$444KSep 30, 2026
Two Sigma124K0.31%US$338KSep 30, 2026
Longaeva Partners L.P.120K0.30%US$328KSep 30, 2026
Walleye Capital LLC120K0.30%US$327KSep 30, 2026
Bridgeway Capital Management, LLC117K0.29%US$320KSep 30, 2026
Goldman Sachs116K0.29%US$315KSep 30, 2026
T. Rowe Price104K0.26%US$285KSep 30, 2026
Cantor Fitzgerald, L. P.100K0.25%US$273KSep 30, 2026
Rangeley Capital, LLC95,0000.23%US$259KSep 30, 2026
Morgan Stanley92,6740.23%US$253KSep 30, 2026
Aisling Capital Management LP88,6070.22%US$241KSep 30, 2026
XTX Topco Ltd81,7270.20%US$223KSep 30, 2026
Dimensional76,9280.19%US$209KSep 30, 2026
BNY72,2150.18%US$197KSep 30, 2026
Rosalind Advisors, Inc.67,5060.17%US$184KSep 30, 2026
Schwab63,6400.16%US$173KSep 30, 2026
UBS63,1560.16%US$172KSep 30, 2026
BNP Paribas56,8670.14%US$155KSep 30, 2026
Prelude Capital Management, LLC54,2640.13%US$148KSep 30, 2026
Empowered Funds, LLC53,0970.13%US$145KSep 30, 2026
Fidelity45,7470.11%US$125KSep 30, 2026
Nuveen45,4910.11%US$124KSep 30, 2026
Aldebaran Capital, LLC39,3570.10%US$107KSep 30, 2026

This page holds 50 of 79 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.11M2.7%US$5.06MJun 30, 2026
iShares Russell 2000 ETF483K1.2%US$2.2MJun 30, 2026
Vanguard Extended Market Index Fund302K0.75%US$1.38MJun 30, 2026
Fidelity Small Cap Index Fund286K0.70%US$1.09MJul 31, 2026
iShares Russell 2000 Value ETF194K0.48%US$884KJun 30, 2026
iShares Micro-Cap ETF79,0840.20%US$361KJun 30, 2026
Schwab Small-Cap Index Fund63,6400.16%US$243KJul 31, 2026
Master Small Cap Index Series41,6520.10%US$190KJun 30, 2026
Fidelity Small Cap Value Index Fund36,5630.09%US$167KJun 30, 2026
Fidelity Extended Market Index Fund36,5300.09%US$153KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Nuveen Small Cap Blend Index Fund35,4020.09%US$135KJul 31, 2026
Ultra-Small Company Market Fund34,0000.08%US$155KJun 30, 2026
Dimensional U.S. Small Cap ETF32,4260.08%US$124KJul 31, 2026
EQ/2000 Managed Volatility Portfolio22,4170.06%US$102KJun 30, 2026
LVIP State Street Small-Cap Index Fund20,5000.05%US$93,480Jun 30, 2026
Fidelity Total Market Index Fund17,1780.04%US$72,148May 31, 2026
Ultra-Small Company Fund16,2930.04%US$74,296Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund15,5240.04%US$70,789Jun 30, 2026
T. Rowe Price Health Care ETF15,3350.04%US$69,928Jun 30, 2026
Fidelity Nasdaq Composite Index Fund12,9440.03%US$54,365May 31, 2026
Global X Russell 2000 ETF12,5390.03%US$47,899Jul 31, 2026
Fidelity Series Total Market Index Fund10,0810.02%US$42,340May 31, 2026
Vanguard Balanced Index Fund9,2690.02%US$42,267Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio9,0000.02%US$41,040Jun 30, 2026
Avantis U.S. Small Cap Equity ETF8,8310.02%US$37,090May 31, 2026
Small Cap Index Fund7,2180.02%US$32,914Jun 30, 2026
Small-Cap Index Portfolio6,8860.02%US$31,400Jun 30, 2026
NVIT Small Cap Index Fund5,3500.01%US$24,396Jun 30, 2026
1290 VT Micro Cap Portfolio5,2540.01%US$23,958Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio4,7550.01%US$21,683Jun 30, 2026
EQ/Small Company Index Portfolio4,2300.01%US$19,289Jun 30, 2026
EQ/AB Small Cap Growth Portfolio4,2300.01%US$19,289Jun 30, 2026
DWS Small Cap Index VIP4,1180.01%US$18,778Jun 30, 2026
T. Rowe Price Small-Cap Index Fund3,952<0.01%US$18,021Jun 30, 2026
Dimensional US Core Equity 1 ETF3,580<0.01%US$13,676Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF3,221<0.01%US$12,304Jul 31, 2026
1290 VT Small Cap Value Portfolio3,094<0.01%US$14,109Jun 30, 2026
SA Small Cap Index Portfolio3,069<0.01%US$11,724Jul 31, 2026
Victory Extended Market Index Fund3,036<0.01%US$11,598Jul 31, 2026
BlackRock Small Cap Index V.I. Fund2,856<0.01%US$13,023Jun 30, 2026
U.S. Small Cap Portfolio2,807<0.01%US$10,723Jul 31, 2026
JNL/DFA U.S. Small Cap Fund2,772<0.01%US$12,640Jun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio2,379<0.01%US$10,848Jun 30, 2026
Nationwide Small Cap Index Fund2,221<0.01%US$8,484Jul 31, 2026
SmallCap Value Fund II2,136<0.01%US$8,160Jul 31, 2026
Venerable Small Cap Index Fund2,096<0.01%US$9,558Jun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio1,106<0.01%US$5,043Jun 30, 2026
PD Small-Cap Value Index Portfolio861<0.01%US$3,926Jun 30, 2026
Penn Series Small Cap Index Fund800<0.01%US$3,648Jun 30, 2026
State Street Total Return V.I.S. Fund662<0.01%US$3,019Jun 30, 2026

This page holds 50 of 61 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Saccomano Nicholas A
Director, Officer: President and CEO
Sale87USD 2.97US$258Sep 21, 2026
Leverone Jason A.
Officer: Chief Financial Officer
Sale302USD 2.97US$897Sep 21, 2026
Saccomano Nicholas A
Director, Officer: President and CEO
Sale86USD 4.40US$378Jun 22, 2026
Leverone Jason A.
Officer: Chief Financial Officer
Sale303USD 4.40US$1,333Jun 22, 2026

Big stakes

StakeStakeSharesDateFiling
AI Biotechnology LLC19.99%9.09MMar 31, 2026Schedule 13D
BVF PARTNERS L P/IL9.99%4.05MSep 30, 2026Schedule 13G
Ra Capital Management, L.P.9.90%4.04MMar 31, 2026Schedule 13G
Anders Hove9.50%3.92MMar 27, 2026Schedule 13G
Coastlands Capital LP6.67%2.7MOct 1, 2026Schedule 13G
StepStone Group LP6.60%2.66MMar 31, 2026Schedule 13G
Shay Capital LLC6.30%810KMay 15, 2025Schedule 13G
Trails Edge Capital Partners, LP6.00%2.41MMar 31, 2026Schedule 13G
Venrock Healthcare Capital Partners III, L.P.5.70%2.31MNov 13, 2026Schedule 13G
Cantor Fitzgerald Securities5.20%670KJun 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Edward Mathers
Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Senti Biosciences Holdings, Inc. (Director · Since at least Jun 8, 2022); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 22, 2023 · Past)
Director · Since at least Apr 8, 2021
Michael Grey
Other companies: Spruce Biosciences, Inc. (Executive Chairman, Director · Since at least Oct 8, 2020); Mirum Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2019); Horizon Pharma PLC (Director · Sep 29, 2011 – May 3, 2018 · Past); BioMarin Pharmaceutical Inc. (Director · Dec 14, 2006 – Mar 5, 2021 · Past); Achillion Pharmaceuticals Inc (Director · Oct 25, 2006 – Dec 18, 2009 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Dec 11, 2008 · Past); SGX Pharmaceuticals Inc (President & CEO, Director · Jan 31, 2006 – Aug 20, 2008 · Past)
Director · Since at least Apr 8, 2021
Isaac Manke
Other companies: Rainier Acquisition Corporation (Director · Since at least Aug 26, 2026); Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Chardan Healthcare Acquisition 2 Corp (Director · Apr 23, 2020 – Apr 23, 2020 · Past)
Director · Since at least Oct 4, 2024
Ashley Hall
Other companies: Structure Therapeutics, Inc. (Chief Development Officer · Since at least Sep 18, 2024); Esperion Therapeutics, Inc. (Chief Development Officer · Feb 26, 2020 – Jan 28, 2021 · Past)
Chief Development Officer · Oct 11, 2020 – Aug 28, 2023 · Past
Bali Muralidhar
Other companies: Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020); Exicure, Inc. (Director · Jun 2, 2021 – Jun 13, 2022 · Past)
Director · Apr 8, 2021 – Jun 6, 2023 · Past
Wendy S Johnson
Other companies: Exagen Inc. (Director · Oct 1, 2020 – Jun 9, 2023 · Past); Armata Pharmaceuticals, Inc. (Director · Sep 8, 2015 – Sep 7, 2017 · Past)
Chief Development Officer · Apr 8, 2021 – Jul 14, 2021 · Past
Jason Leverone
Other companies: Viridian Therapeutics, Inc. (Chief Financial Officer · Jan 18, 2021 – Jan 18, 2021 · Past)
Chief Financial Officer · Since at least Oct 4, 2024
Johan Kordel
Other companies: Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Feb 4, 2014 · Past)
Director · Apr 8, 2021 – Apr 8, 2021 · Past
Samuel Agresta
Other companies: Foghorn Therapeutics Inc. (Chief Medical Officer · Oct 22, 2020 – Sep 11, 2023 · Past)
Chief Medical Officer · Since at least Oct 4, 2024
Stacey Denenberg Seltzer
Other companies: Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past)
Director · Apr 8, 2021 – Jun 6, 2023 · Past
All 27 people
PersonSeat
Valerie Jansen
Other companies: Elevation Oncology Inc (CHIEF MEDICAL OFFICER · Jan 6, 2023 – Feb 15, 2025 · Past)
Director · Since at least Oct 4, 2024
Aaron GoodwinVice President of Pharmaceutical Sciences and Supply Chain · Since at least Nov 4, 2026
Andrew PhillipsDirector · Since at least Mar 27, 2026
David MareskaVice President, Discovery Chemistry · Since at least Nov 4, 2026
Dylan HartleyChief Scientific Officer · Since at least Oct 4, 2024
Gregory J FlesherPresident and CEO, Director · Apr 8, 2021 – Dec 9, 2022 · Past
James BlakeSenior Vice President of Computational Drug Discovery · Since at least Nov 4, 2026
Jennifer LamVP of Finance & Administration · Mar 31, 2022 – Dec 9, 2022 · Past
Jim WongVice President, Biological Sciences · Since at least Nov 4, 2026
Kevin S. LitwilerSenior Vice President of DMPK and Clinical Pharmacology · Since at least Nov 4, 2026
Liam RatcliffeDirector · Since at least Mar 27, 2026
Mark L. BoysSenior Vice President of Discovery Chemistry · Since at least Nov 4, 2026
Nicholas A. SaccomanoPresident and CEO, Director · Since at least Jun 22, 2026
Qian ZhaoVice President and Distinguished Fellow · Since at least Nov 4, 2026
R. Michael CarruthersDirector · Since at least Nov 5, 2026
Robbie AltonSenior Vice President of Clinical Operations · Since at least Nov 4, 2026
Rogan NunnGeneral Counsel and Secretary · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about OnKure Therapeutics, Inc.